Abstract
Efalizumab is a humanized, monoclonal IgG1 antibody that binds to the α-subunit of lymphocyte function associated antigen (LFA)-1, blocking the interaction between LFA-1 and intercellular adhesion molecule-1. The result is a reduction in T cell activation, an inhibition of the trafficking and recruitment of T cells to the dermis and epidermis, and a decrease in the reactivation of T cells at several steps in the psoriasis pathogenesis. The clinical responses seen in efalizumab trials have demonstrated that this medication is efficacious, especially in long-term treatment. Adverse events observed in efalizumab-treated patients have been minor. Psoriasis rebound following discontinuation of treatment, while serious, has been controlled through transition to other therapies. Subcutaneous injection allows for administration outside the clinic.
Keywords: Anti-CD11a, Biologic, Efalizumab, LFA-1, Psoriasis, Raptiva(™), T cell
Reviews on Recent Clinical Trials
Title: Efalizumab: A Biological Agent for the Treatment of Psoriasis
Volume: 1 Issue: 2
Author(s): Sarah Hodulik and Suhail Hadi
Affiliation:
Keywords: Anti-CD11a, Biologic, Efalizumab, LFA-1, Psoriasis, Raptiva(™), T cell
Abstract: Efalizumab is a humanized, monoclonal IgG1 antibody that binds to the α-subunit of lymphocyte function associated antigen (LFA)-1, blocking the interaction between LFA-1 and intercellular adhesion molecule-1. The result is a reduction in T cell activation, an inhibition of the trafficking and recruitment of T cells to the dermis and epidermis, and a decrease in the reactivation of T cells at several steps in the psoriasis pathogenesis. The clinical responses seen in efalizumab trials have demonstrated that this medication is efficacious, especially in long-term treatment. Adverse events observed in efalizumab-treated patients have been minor. Psoriasis rebound following discontinuation of treatment, while serious, has been controlled through transition to other therapies. Subcutaneous injection allows for administration outside the clinic.
Export Options
About this article
Cite this article as:
Hodulik Sarah and Hadi Suhail, Efalizumab: A Biological Agent for the Treatment of Psoriasis, Reviews on Recent Clinical Trials 2006; 1 (2) . https://dx.doi.org/10.2174/157488706776876436
DOI https://dx.doi.org/10.2174/157488706776876436 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway
Current Pharmaceutical Design Quinones Derived from Plant Secondary Metabolites as Anti-cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Recent Progress in the Identification and Clinical Evaluation of Inhibitors of the Mitotic Kinesin KSP
Current Topics in Medicinal Chemistry Receptor Tryosine Kinase Inhibitors as Potent Weapons in War Against Cancers
Current Pharmaceutical Design A New 4-phenyl-1,8-naphthyridine Derivative Affects Carcinoma Cell Proliferation by Impairing Cell Cycle Progression and Inducing Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Exosomes: A Role for Naturally Occurring Nanovesicles in Cancer Growth, Diagnosis and Treatment
Current Gene Therapy Overview of Mechanisms of Cancer Stem Cell Drug Resistance
Current Signal Transduction Therapy Bone Morphogenetic Proteins and its Receptors; Therapeutic Targets in Cancer Progression and Bone Metastasis?
Current Pharmaceutical Design Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors
Recent Patents on Anti-Cancer Drug Discovery Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design A Five-gene Signature for Predicting the Prognosis of Colorectal Cancer
Current Gene Therapy Metastasis Suppressors: Basic and Translational Advances
Current Pharmaceutical Biotechnology The Anticancer Properties of Dietary Polyphenols and its Relation with Apoptosis
Current Pharmaceutical Design The Natural Tumor Suppressor Protein Maspin and Potential Application in Non Small Cell Lung Cancer
Current Pharmaceutical Design miR-4319 Suppresses the Growth of Esophageal Squamous Cell Carcinoma Via Targeting NLRC5
Current Molecular Pharmacology Molecular Dynamics in Esophageal Adenocarcinoma: Who’s in Control?
Current Cancer Drug Targets Elevated O-GlcNAcylation Promotes Malignant Phenotypes of Hypopharyngeal Squamous Cell Carcinoma by Stabilizing Nrf2 through Regulation of the PI3K/Akt Pathway
Anti-Cancer Agents in Medicinal Chemistry HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Cutaneous Melanoma: Fishing with Chips
Current Molecular Medicine